|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
January 21, 2006Schering AG Mulling Whether to Acquire Complete Rights to Betaferon
Drug maker Schering AG said Thursday it is still mulling whether to acquire completely the rights to multiple sclerosis treatment Betaferon.
Schering has to decide whether it wants to buy the complete rights from U.S. biotech Chiron Corp., which Novartis AG is planning to take over by mid-2006. In an agreement between Schering and Chiron, Schering has worldwide marketing rights to the drug, while Chiron, which manufactures the drug for the United States, gets 22 percent of worldwide Betaferon revenue. Novartis' offer to take over Chiron at the end of October triggered a clause in the agreement, according to which Novartis would have the right to produce and market the drug in parallel with Schering from 2008 if Schering does not buy the exclusive rights. |